Fiduciary Management Inc. WI Has $87.65 Million Position in Icon Plc $ICLR

Fiduciary Management Inc. WI reduced its position in shares of Icon Plc (NASDAQ:ICLR) by 14.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 480,996 shares of the medical research company’s stock after selling 79,942 shares during the quarter. Fiduciary Management Inc. WI owned 0.60% of Icon worth $87,647,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in ICLR. Parallel Advisors LLC increased its stake in shares of Icon by 57.3% in the fourth quarter. Parallel Advisors LLC now owns 703 shares of the medical research company’s stock worth $128,000 after acquiring an additional 256 shares during the last quarter. Vise Technologies Inc. acquired a new position in shares of Icon in the fourth quarter worth $662,000. Daiwa Securities Group Inc. increased its stake in shares of Icon by 16.7% in the fourth quarter. Daiwa Securities Group Inc. now owns 34,994 shares of the medical research company’s stock worth $6,377,000 after acquiring an additional 5,018 shares during the last quarter. State of Wyoming increased its stake in shares of Icon by 42.3% in the fourth quarter. State of Wyoming now owns 2,181 shares of the medical research company’s stock worth $397,000 after acquiring an additional 648 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Icon by 5.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 473,175 shares of the medical research company’s stock worth $86,222,000 after acquiring an additional 24,408 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Icon Price Performance

Shares of ICLR stock opened at $149.45 on Friday. The firm’s 50 day moving average price is $117.51 and its two-hundred day moving average price is $140.85. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.10 and a current ratio of 1.10. The stock has a market cap of $12.07 billion, a PE ratio of 24.26, a PEG ratio of 10.13 and a beta of 1.26. Icon Plc has a 52-week low of $66.57 and a 52-week high of $211.00.

Icon (NASDAQ:ICLR) last posted its earnings results on Wednesday, May 27th. The medical research company reported $2.21 earnings per share for the quarter. The company had revenue of $2.11 billion for the quarter. Icon had a net margin of 5.98% and a return on equity of 9.50%. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. As a group, analysts forecast that Icon Plc will post 9.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $165.00 price objective on shares of Icon in a report on Friday, May 29th. DA Davidson set a $164.00 price objective on shares of Icon in a research report on Monday, June 1st. Leerink Partners set a $145.00 price objective on shares of Icon in a research report on Thursday, May 28th. Bank of America reaffirmed an “outperform” rating on shares of Icon in a research report on Monday, June 1st. Finally, Royal Bank Of Canada upped their price objective on shares of Icon from $123.00 to $126.00 and gave the company a “sector perform” rating in a research report on Friday, May 29th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Icon has a consensus rating of “Hold” and a consensus price target of $156.44.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.